Multi-target RNA amplification detection method and detection kit

Through multi-target RNA amplification detection method, combined with reverse transcriptase, RNA polymerase and fluorescence detection technology, the existing RNA detection methods are solved in the low sensitivity and complicated operation problems, and efficient and accurate multi-target RNA detection is achieved, suitable for multiple A kind of application scenario.

CN118910227APending Publication Date: 2024-11-08SHANGHAI RENDU BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411140351.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing RNA detection methods have problems such as low sensitivity, long experimental cycle, cumbersome operation and multiple pairs of primer inhibition. It is difficult to improve the detection efficiency of complex systems when detecting multiple subtypes or co-testing multiple objects.

Method used

Using multi-target RNA amplification detection method, the combination of reverse transcriptase, RNA polymerase and fluorescence detection technology is divided into multiple reaction steps, including extraction, first-stage amplification and second-stage amplification, using specific primers and The probe is aliquoted to achieve high sensitivity qualitative detection of multi-target RNA.

Benefits of technology

It improves the sensitivity and efficiency of RNA detection, reduces the detection cycle, and avoids the mutual inhibition of multiple pairs of primers. It is suitable for clinical testing, blood screening and food safety inspections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910227A_ABST
    Figure CN118910227A_ABST
Patent Text Reader

Abstract

The invention discloses a multi-target RNA method detection method and a detection kit, and belongs to the technical field of RNA detection. The multi-target RNA detection method provided by the invention comprises the steps of multi-target RNA extraction, first-stage amplification reaction, second-stage amplification reaction and fluorescence detection, and in the second-stage amplification reaction, a product of the first-stage amplification reaction is sub-packaged into a plurality of reaction units; according to the present invention, the multiple target RNAs in the to-be-detected sample can be detected with high sensitivity, and the method only needs the one-time multi-target RNA extraction operation and the one-time first-stage amplification reaction operation so as to significantly improve the detection efficiency, such that the multiple target RNAs in the to-be-detected sample can be detected with high sensitivity, and the detection efficiency can be significantly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of RNA detection technology in the field of biotechnology, and specifically relates to a multi-target RNA detection method and a detection kit. Background Art

[0002] RNA exists in various forms in organisms, including mRNA, miRNA, rRNA, and tRNA, and is involved in various physiological processes such as gene expression, gene regulation, and metabolic regulation. Given that the amount of RNA in organisms with life activities is much higher than that in inactive organisms, RNA is also used as a marker for identifying living cells and bacteria. On the other hand, the number of RNA copies in cells, bacteria and other organisms is much higher than the number of DNA copies, and some RNAs are highly conservative and can be used as markers for species identification. Therefore, highly sensitive species identification can be performed based on RNA. Moreover, with the development of life science and technology, it has been found that RNA is also involved in regulating the occurrence and development of a large number of diseases, becoming a new molecular marker for disease diagnosis, efficacy monitoring and prediction.

[0003] RNA has the general characteristics of poor stability and easy degradation. Some RNA fragments are short, making sample preparation difficult. All of these factors lead to difficulties in RNA detection. However, with the iterative development of life science technology, a variety of RNA detection methods have been established.

[0004] Northern Blot is the earliest established RNA detection method. Its principle is to hybridize the labeled oligonucleotide probe with the target RNA transferred on the nitrocellulose membrane, and finally develop and detect it. This method is considered to be the standard method for detecting RNA, but it has the disadvantages of long experimental cycle, cumbersome experimental operation, low detection sensitivity, and large sample demand.

[0005] Reverse transcription-quantitative PCR (RT-qPCR) is currently one of the main methods for detecting low-expression RNA. This method first reverse transcribes RNA into the corresponding cDNA, and then uses cDNA as a template for PCR. However, this method still has disadvantages such as difficulty in RNA extraction and purification, high and cumbersome experimental operation requirements, long experimental cycle, and low detection sensitivity, which limit its clinical application.

[0006] The RNA detection methods established in the prior art all have many defects, and when the detection object has multiple subtypes or multiple objects need to be tested together, it is difficult to avoid the mutual inhibition of multiple pairs of primers in a single reaction system, affecting the overall amplification efficiency. Therefore, how to improve the sensitivity of complex systems is an important problem that currently limits the detection efficiency of RNA detection methods. Summary of the invention

[0007] In view of one or more problems existing in the prior art, one aspect of the present invention provides a multi-target RNA amplification detection method for non-disease diagnosis purposes, which comprises the following steps:

[0008] 1) Extraction of multi-target RNA: Mixing a sample to be tested with a nucleic acid extract, extracting multi-target RNA in the sample to be tested, and obtaining an RNA sample; wherein the nucleic acid extract comprises a first primer and a capture probe specific to each target RNA in the multi-target RNA, the 3' end sequence of the first primer is a sequence that specifically binds to the corresponding target RNA, and the 5' end sequence is a promoter sequence, and the capture probe is used to capture the corresponding target RNA;

[0009] 2) First stage amplification reaction: adding detection solution 1 and enzyme solution to the RNA sample obtained in step 1), mixing and reacting (specifically, first adding detection solution 1 to the RNA sample obtained in step 1), mixing and reacting (reacting at 37-45° C. for 3-10 min), and then adding enzyme solution to the mixed solution, mixing and reacting (reacting at 37-45° C. for 3-10 min)), to obtain a first stage amplification product; wherein the detection solution 1 contains a second primer specific to each target RNA in the multi-target RNA, the second primer is used to cooperate with the first primer to amplify the corresponding target RNA, and the enzyme solution contains reverse transcriptase and RNA polymerase;

[0010] 3) Second-stage amplification reaction and fluorescence detection: The first-stage amplification product obtained in step 2) is packaged so that the number of reaction units after packaging is not less than the number of types of multi-target RNAs, and detection solutions 2 for different target RNAs are added to the packaged reaction units respectively, and after mixing, constant-temperature amplification reaction and fluorescence detection are performed to obtain qualitative determination results of each target RNA respectively; wherein the detection solution 2 for different target RNA contains a first primer and a target detection probe corresponding to the target RNA it targets.

[0011] In some embodiments, in step 1), the promoter sequence is a T7 promoter sequence, and its nucleotide sequence is shown in SEQ ID NO:1.

[0012] In some embodiments, the capture probe is connected to a solid support. Optionally, the content of the solid support in the nucleic acid extract is 50-500 mg / L; further optionally, the solid support is a magnetic particle.

[0013] In some embodiments, the RNA is miRNA or non-miRNA, wherein the non-miRNA includes mRNA, rRNA, and tRNA.

[0014] In some embodiments, the operation of step 1) includes:

[0015] 1-1) Mix the sample to be tested with the nucleic acid extract, incubate at 55-95°C for 10-15 minutes, let stand at room temperature until the mixture returns to room temperature, and magnetize on a magnetic stand for at least 5 minutes, and discard the supernatant;

[0016] 1-2) adding washing solution to the product of step 1-1) to resuspend, adsorbing on a magnetic stand for 5 to 15 minutes, and discarding the supernatant; and

[0017] 1-3) Repeat steps 1-2) to obtain RNA samples;

[0018] Optionally, the washing solution in step 1-2) comprises: 5-50 mM HEPES, 50-500 mM NaCl, 0.5-1.5% SDS, and 1-10 mM EDTA.

[0019] In some embodiments, in step 1), the nucleic acid extract comprises: 250-800 mM HEPES, 4-10% LLS, 1-50 μM capture probe for each target, 50-500 mg / L solid support, and 0.01-2 μM first primer for each target.

[0020] In some embodiments, in step 2),

[0021] The reaction conditions are: 37-45°C for 3-10 min; and / or

[0022] The detection solution 1 comprises: 10-50 mM Tris, 20-90 mM KCl, 10-50 mM MgCl2, 0.1-10 mM NTPs, 0.1-10 mM dNTPs, 5-40% Glycerol, 0-25% DMSO, 0.01-2 μM of the second primer for each target; and / or

[0023] The enzyme solution contains: 100-9000U reverse transcriptase, 100-5000U RNA polymerase, 20-100mM Tris, 0.1-1% TritonX-100, 30-300mM KCl, 0.01-0.5mM EDTA, 0.1-2mM DTT, and 20-50% Glycerol.

[0024] In some embodiments, in step 3),

[0025] The detection solutions 2 for different target RNAs all contain: 10-50 mM Tris, 20-90 mM KCl, 10-50 mM MgCl2, 0.1-10 mM NTPs, 0.1-10 mM dNTPs, 5-40% Glycerol, 0-25% DMSO, 0.01-2 μΜ of a first primer corresponding to the target RNA, and 0.01-2 μΜ of a target detection probe corresponding to the target RNA; and / or

[0026] The target detection probe is selected from any one of the following: molecular beacon, fluorescence resonance, scorpion probe, fluorescence amplification and molecular torch technology.

[0027] In some embodiments, in step 3), the reaction conditions of the isothermal amplification are: 37-45° C. for 20-60 min.

[0028] In some embodiments, the multi-target RNA is selected from two or more (e.g., three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or all ten) of the following mRNAs: VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, EV71; wherein:

[0029] The nucleotide sequences of the first primers for mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 12 to 21, respectively;

[0030] The nucleotide sequences of the capture probes for mRNA of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 22 to 31, respectively;

[0031] The nucleotide sequences of the second primers for mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 32 to 41, respectively;

[0032] The nucleotide sequences of the target capture probes for mRNA of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 42 to 51, respectively.

[0033] Another aspect of the present invention provides a multi-target RNA amplification detection kit, comprising:

[0034] Nucleic acid extract: it contains a first primer and a capture probe specific to each target RNA in multiple target RNAs, the 3' end sequence of the first primer is a sequence that specifically binds to the corresponding target RNA, and the 5' end sequence is a promoter sequence, and the capture probe is used to capture the corresponding target RNA; optionally, the nucleic acid extract contains: 250-800mM HEPES, 4-10% LLS, 1-50μΜ capture probe for each target, 50-500mg / L solid support, 0.01-2μΜ first primer for each target;

[0035] Detection solution 1: comprising a second primer specific to each target RNA in the multi-target RNA, wherein the second primer is used to cooperate with the first primer to amplify the corresponding target RNA; optionally, the detection solution 1 comprises: 10-50mMTris, 20-90mM KCl, 10-50mM MgCl2, 0.1-10mM NTPs, 0.1-10mM dNTPs, 5-40% Glycerol, 0-25% DMSO, and 0.01-2μΜ second primer for each target;

[0036] Detection liquid 2: it includes a plurality of detection liquids 2 corresponding to each target RNA in the multiple target RNAs, and each detection liquid 2 contains a first primer and a target detection probe corresponding to its target RNA; optionally, each detection liquid 2 contains: 10-50mM Tris, 20-90mM KCl, 10-50mM MgCl2, 0.1-10mM NTPs, 0.1-10mM dNTPs, 5-40% Glycerol, 0-25% DMSO, 0.01-2μΜ of the first primer corresponding to the target RNA, 0.01-2μΜ of the target detection probe corresponding to the target RNA; and

[0037] Enzyme solution: it contains reverse transcriptase and RNA polymerase; optionally, the enzyme solution contains: 100-9000U reverse transcriptase, 100-5000U RNA polymerase, 20-100mM Tris, 0.1-1% TritonX-100, 30-300mM KCl, 0.01-0.5mM EDTA, 0.1-2mM DTT, 20-50% Glycerol.

[0038] The multi-target RNA amplification detection method provided based on the above technical solution adopts a combination of reverse transcriptase, RNA polymerase and molecular beacon (Molecular Beacon), fluorescence resonance (iFret, Fret), scorpion probe (Scorpionprobe), fluorescence amplification (Amplifluor) or molecular torch technology (Molecular Torch) and other fluorescence detection technologies to separate multiple reaction steps, including multi-target RNA extraction in the sample to be tested, first-stage amplification reaction, second-stage amplification reaction, constant temperature amplification and fluorescence detection, and in the second-stage amplification reaction, the product obtained by the first-stage amplification reaction is divided into multiple reaction units (for example, according to the number of types of multi-target RNA, the same number of reaction units are averagely divided), and the detection solution 2 for each target in the multi-target RNA is added to each reaction unit for independent detection, which can fully detect each target RNA in the sample to be tested, has high sensitivity, and the method provided by the present invention only requires one multi-target RNA extraction operation and one first-stage amplification reaction operation, so the detection efficiency can also be significantly improved.

[0039] The basic principle of the method provided by the present invention can be referred to Figure 1 , wherein each first primer will recognize the 3' end of the corresponding target RNA and synthesize RNA / cDNA hybrid chain under the action of reverse transcriptase. Reverse transcriptase hydrolyzes the RNA chain in the RNA / cDNA hybrid chain, and at the same time, each second primer will specifically recognize the sequence corresponding to the newly synthesized single-stranded cDNA, synthesize the corresponding double-stranded cDNA under the action of reverse transcriptase, and introduce the corresponding second primer sequence. RNA polymerase recognizes the promoter sequence in the double-stranded cDNA, and transcribes and synthesizes a new RNA containing the target RNA sequence, the corresponding first primer sequence and the corresponding second primer sequence. The corresponding first primer and the second primer are synchronously amplified at constant temperature with the newly transcribed corresponding RNA as a template to amplify more corresponding RNA negative chains. There are target detection probes complementary to the RNA negative chains in the reaction system. As the number of RNA negative chains in the system increases, the number of target detection probes hybridized with it also increases continuously. The change of the fluorescence signal in the system is synchronously detected by the detector, and the multiple target RNAs in the sample to be tested are qualitatively detected according to the time and intensity of the change of the fluorescence signal.

[0040] Specifically, the reaction process refers to Figure 2As shown. During the nucleic acid extraction process, the first primers corresponding to all targets are added, and the 3' end of each first primer will specifically recognize the corresponding target RNA, and the 5' end of each first primer is a promoter sequence; at the same time, the 5' end of the sample RNA to be tested is bound to the solid phase support containing the corresponding capture probe; after subsequent washing, the excessive first primers and other impurities are removed to obtain the RNA sample. The subsequent amplification reaction is divided into two stages: the first stage: the detection solution 1 containing the second primers corresponding to all targets and the enzyme solution and other related reaction raw materials are added. Under the action of reverse transcriptase, the pre-amplified body bound by each first primer is extended, and a cDNA containing the target RNA sequence and the corresponding first primer sequence is formed. Subsequently, the RNA chain in the RNA / cDNA hybrid chain is hydrolyzed under the action of RNaseH of the reverse transcriptase, and the added second primer is extended with the newly synthesized single-stranded cDNA as a template to synthesize a double-stranded cDNA containing the target RNA sequence, the corresponding first primer sequence and the corresponding second primer sequence. RNA polymerase recognizes the promoter sequence in the double-stranded cDNA and transcribes and synthesizes RNA containing the target RNA sequence, the corresponding first primer sequence and the corresponding second primer sequence. Each second primer then uses the newly transcribed corresponding RNA as a template to synthesize a cDNA containing the target RNA sequence, the corresponding first primer sequence and the corresponding second primer sequence, but the cDNA does not have a promoter sequence. Similarly, the RNA chain in the RNA / cDNA hybrid chain is also hydrolyzed under the action of RNaseH of the reverse transcriptase to obtain a single-stranded cDNA (first-stage amplification product). Since there is a lack of sufficient first primers in the reaction system at this moment, the first-stage amplification reaction is terminated. Second stage: The first-stage amplification product is packaged, and the first primers and target detection probes corresponding to each single target are added respectively. Each first primer will specifically recognize the corresponding single-stranded cDNA in the first-stage amplification product. Under the action of RNA polymerase, a new RNA containing the target RNA sequence, the corresponding first primer sequence and the corresponding second primer sequence (second-stage amplification product) is transcribed and synthesized. These newly synthesized RNAs are specifically bound by the corresponding target detection probes and generate fluorescent signals. At the same time, each second primer also uses the newly synthesized corresponding RNA as a template to synthesize a new round of first-stage amplification products. Use a detector (optional ABI7000, 7300, 7500, 7700, 7900 series, Stratagen MPX3000 series or BaradiQ series, fully automatic nucleic acid detection and analysis system (AutoSAT)) to synchronously detect changes in the fluorescence signal in the system, and qualitatively detect RNA samples based on the time and intensity of the changes in the fluorescence signal. Compared with the prior art, the multi-target RNA amplification detection method provided by the present invention has the following advantages:

[0041] (1) The method of the present invention does not require RNA purification, and the experimental process is shorter and more efficient.

[0042] (2) The detection object of the present invention is RNA, which can be used as a method for detecting pathogens with biological activity.

[0043] (3) The final amplification product of the present invention is RNA, which is easily degraded and has lower biological hazards.

[0044] (4) In the second-stage amplification reaction of the present invention, RNA amplification and detection are both carried out in the same closed space, and the entire process does not require temperature rise and fall cycles, which greatly reduces the detection time.

[0045] (5) The present invention effectively solves the problem of mutual inhibition of components in a complex reaction system containing multiple pairs of primers and multiple different target detection probes by packaging the first-stage amplification products and then adding the first primers and target detection probes corresponding to each target. At the same time, the detection of different targets is carried out in the same closed space before the second-stage amplification reaction occurs, which greatly improves the efficiency of amplification detection and is very suitable for the inspection of low-content RNA.

[0046] In summary, the detection method provided by the present invention has the advantages of high reaction system amplification efficiency, high detection sensitivity, short detection cycle and high accuracy. It is suitable for nucleic acid detection in the fields of clinical testing, blood screening, food safety inspection and environmental monitoring, and is suitable for large-scale promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 This is an exemplary basic principle diagram of the multi-target RNA amplification detection method provided by the present invention.

[0048] Figure 2 This is an exemplary reaction flow chart of the multi-target RNA amplification detection method provided by the present invention.

[0049] Figure 3-Figure 4 They are the real-time fluorescence amplification curves of two repeated experiments on VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 in the control group 1 and the experimental group in Example 1, respectively.

[0050] Figure 5-Figure 7 These are the real-time fluorescence amplification curves of two repeated experiments on VC, Sal.Spp., TB, SH, IAV, HBV, and HCV in the experimental group, control group 1, and control group 2 in Example 2, respectively.

[0051] Figure 8-Figure 10 These are the real-time fluorescence amplification curves of two repeated experiments on VC, Sal.Spp., TB, SH and IAV in the experimental group, control group 1 and control group 2 in Example 3, respectively.

[0052] Figure 11-13These are the real-time fluorescence amplification curves of two repeated experiments on VC, Sal.Spp., and TB in the experimental group, control group 1, and control group 2 in Example 4, respectively.

[0053] Figure 14-16 These are the real-time fluorescence amplification curves of two repeated experiments on VC, Sal.Spp., TB, SH and IAV in the experimental group, control group 1 and control group 2 in Example 5, respectively.

[0054] Figure 17-Figure 19 These are the real-time fluorescence amplification curves of two repeated experiments on VC, Sal.Spp., and TB in the experimental group, control group 1, and control group 2 in Example 2, respectively. DETAILED DESCRIPTION

[0055] In view of the many defects of RNA amplification detection methods existing in the prior art, the multi-target RNA amplification detection method provided by the present invention divides the entire amplification process into two stages, by packaging the first-stage amplification products before the second-stage amplification, and then adding the second-stage amplification detection liquid for each target (also referred to as detection liquid 2 herein) to achieve high-sensitivity qualitative detection of each target in the multi-target test sample. The system achieves efficient amplification and rapid detection of target RNA under the action of reverse transcriptase, RNA polymerase and target detection probe for the primer pairs of each target in the system. The experimental method provided by the present invention has high detection sensitivity and only requires constant temperature amplification, which is easier to realize automated detection and is suitable for large-scale promotion and application.

[0056] The content of the present invention is described in detail below with reference to specific embodiments.

[0057] Hereinafter, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present invention. Therefore, the description of the embodiments is considered to be exemplary and non-restrictive in nature.

[0058] The methods used in the following examples are all conventional methods unless otherwise specified. For specific steps, please refer to: Molecular Cloning: A Laboratory Manual (Sambrook, J., Russell, David W., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, NY, Cold Spring Harbor).

[0059] The methods for obtaining various biological materials described in the examples are only provided as a way of obtaining them in an experiment to achieve the specific disclosed purpose, and should not be construed as limiting the sources of the biological materials of the present invention. In fact, the sources of the biological materials used are extensive, and any biological materials that can be obtained without violating laws and moral ethics can be replaced and used according to the instructions in the examples.

[0060] All primers, probes and in vitro transcribed RNA products mentioned in the present invention are synthesized using existing techniques.

[0061] The extraction of RNA from the sample to be tested mentioned in the present invention adopts a specific magnetic bead capture extraction method. The method provided by the present invention can be used for the detection of miRNA and non-miRNA, wherein non-miRNA includes rRNA, tRNA, mRNA, etc. The sample to be tested can be a clinical test sample (such as samples for detecting group B streptococci during prenatal examinations, Staphylococcus aureus during skin infections, etc.), a blood sample, an animal and plant tissue sample, a food sample (such as samples for detecting common food pathogenic microorganisms such as Escherichia coli, Salmonella, and Shigella), and an environmental monitoring sample (such as samples for detecting fecal coliforms and fecal streptococci contaminated by feces), etc.

[0062] The following reagents and polymerases can be used in the present invention: Tris, TritonX-100, KCl, MgCl2, NTPs, dNTPs, EDTA, DTT, Glycerol, DMSO, reverse transcriptase and RNA polymerase, etc.

[0063] The components of the nucleic acid extract involved in the present invention may be: 250-800mM HEPES, 4-10% LLS, 1-50μΜ specific capture probe for each target, 50-500mg / L magnetic beads, 0.01-2μΜ first primer for each target (containing T7 promoter sequence, the nucleotide sequence of which is shown in SEQ ID NO: 1); the components of the nucleic acid extract specifically used in the following embodiments are: 500mM HEPES, 6% LLS, 25μΜ specific capture probe for each target (i.e., the concentration of each specific capture probe is 25μΜ), 250mg / L magnetic beads, 0.5μΜ specific first primer for each target (i.e., the concentration of each specific first primer is 0.5μΜ);

[0064] The components of the detection solution 1 involved in the present invention may be: 10-50mM Tris, 20-90mM KCl, 10-50mM MgCl2, 0.1-10mM NTPs, 0.1-10mM dNTPs, 5-40% Glycerol, 0-25% (e.g., 1-25%) DMSO, 0.01-2μΜ specific second primer for each target (consistent with the target RNA sequence); the components of the detection solution 1 specifically used in the following embodiments are: 50mM Tris, 35mM KCl, 20mM MgCl2, 4mM NTPs, 1mM dNTPs, 10% Glycerol, 5% DMSO, 0.3μΜ specific second primer for each target;

[0065] The components of the detection solution 2 involved in the present invention may be: 10-50mM Tris, 20-90mM KCl, 10-50mM MgCl2, 0.1-10mM NTPs, 0.1-10mM dNTPs, 5-40% Glycerol, 0-25% (e.g., 1-25%) DMSO, 0.01-2μΜ specific first primer for each target, 0.01-2μΜ specific target detection probe for each target (complementary binding to the amplified product RNA); the components of the detection solution 2 specifically used in the following embodiments are: 50mMTris, 35mM KCl, 20mM MgCl2, 4mM NTPs, 1mM dNTPs, 10% Glycerol, 5% DMSO, 0.3μΜ specific first primer for each target, 0.2μΜ specific target detection probe for each target;

[0066] The components of the enzyme solution involved in the present invention may be: 100-9000U reverse transcriptase (such as M-MLV reverse transcriptase or AMV reverse transcriptase, RD BioSciences, USA), 100-5000U RNA polymerase (such as purchased from RD BioSciences, USA), 20-100mM Tris, 0.1-1% TritonX-100, 30-300mM KCl, 0.01-0.5mM EDTA, 0.1-2mM DTT, 20-50% Glycerol; the components of the enzyme solution specifically used in the following examples are: 2000U reverse transcriptase (M-MLV reverse transcriptase, RD BioSciences, USA), 2000U T7 RNA polymerase (RD BioSciences, USA), 20mMTris, 0.5% TritonX-100, 30mM KCl, 0.1mM EDTA, 0.3mM DTT, 25% Glycerol.

[0067] Example 1: Detection of a sample containing multiple target RNAs

[0068] In this embodiment, the RNA of the sample to be tested containing target RNA of Vibrio cholerae (VC), Salmonella (Sal.Spp.), Mycobacterium tuberculosis (TB), Shigella (SH), universal influenza A virus (IAV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV-1), human immunodeficiency virus type Ⅰ (HIV), enterovirus 71 (EV71) is detected, and the specific steps are as follows:

[0069] (1.1) Preparation of RNA samples to be tested:

[0070] Preparation of RNA samples: In this example, in vitro transcribed mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 (nucleotide sequences are shown in SEQ ID NOs: 2 to 11, respectively) were mixed as RNA samples to be tested. The RNA samples to be tested were diluted so that the concentration of each target RNA in the RNA samples to be tested was 5 copies / μl, and used as RNA samples for the following experimental groups, control group 1, and control group 2.

[0071] (1.2) Preparation of experimental reagents:

[0072] (1.2.1) Preparation of nucleic acid extraction solution:

[0073] The nucleic acid extract of the experimental group contains specific first primers for VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 (the nucleotide sequences are shown in SEQ ID NOs: 12 to 21, respectively), and poly T-modified magnetic beads (solid support) of specific capture probes for each target (the nucleotide sequences of the specific capture probes for the above target RNAs are shown in SEQ ID NOs: 22 to 31, respectively).

[0074] Control group 1 nucleic acid extract-1: containing a specific first primer for VC (the nucleotide sequence is shown in SEQ ID NO: 12); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 22);

[0075] Control group 1 nucleic acid extract-2: containing a specific first primer for Sal. Spp. (the nucleotide sequence is shown in SEQ ID NO: 13); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 23);

[0076] Control group 1 nucleic acid extract-3: containing a specific first primer for TB (the nucleotide sequence is shown in SEQ ID NO: 14); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 24);

[0077] Control group 1 nucleic acid extract-4: containing a specific first primer for SH (the nucleotide sequence is shown in SEQ ID NO: 15); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 25);

[0078] Control group 1 nucleic acid extract-5: containing a specific first primer for IAV (the nucleotide sequence is shown in SEQ ID NO: 16); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 26);

[0079] Control group 1 nucleic acid extract-6: containing a specific first primer for HBV (the nucleotide sequence is shown in SEQ ID NO: 17); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 27);

[0080] Control group 1 nucleic acid extract-7: containing a specific first primer for HCV (the nucleotide sequence is shown in SEQ ID NO: 18); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 28);

[0081] Control group 1 nucleic acid extract-8: containing a specific first primer for HSV-1 (the nucleotide sequence is shown in SEQ ID NO: 19); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 29);

[0082] Control group 1 nucleic acid extract-9: containing a specific first primer for HIV (nucleotide sequence as shown in SEQ ID NO: 20); and a specific capture probe (nucleotide sequence as shown in SEQ ID NO: 30);

[0083] Control group 1 nucleic acid extract-10: contains a specific first primer for EV71 (the nucleotide sequence is shown in SEQ ID NO: 21); and a specific capture probe (the nucleotide sequence is shown in SEQ ID NO: 31).

[0084] Nucleic acid extract of control group 2: It is the same as the nucleic acid extract of the experimental group.

[0085] (1.2.2) Preparation of test solution 1:

[0086] Experimental group detection solution 1: contains specific second primers for VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 (the nucleotide sequences are shown in SEQ ID NOs: 32 to 41, respectively).

[0087] Control group 1 test solution 1-1: containing a specific second primer for VC (nucleotide sequence as shown in SEQ ID NO: 32);

[0088] Control group 1 test solution 1-2: containing a specific second primer for Sal. Spp. (nucleotide sequence as shown in SEQ ID NO: 33);

[0089] Control group 1 test solution 1-3: containing a second primer specific for TB (the nucleotide sequence is shown in SEQ ID NO: 34);

[0090] Control group 1 test solution 1-4: containing a specific second primer for SH (the nucleotide sequence is shown in SEQ ID NO: 35);

[0091] Control group 1 test solution 1-5: containing a specific second primer for IAV (nucleotide sequence as shown in SEQ ID NO: 36);

[0092] Control group 1 test solution 1-6: containing a specific second primer for HBV (nucleotide sequence as shown in SEQ ID NO: 37);

[0093] Control group 1 test solution 1-7: containing a second primer specific for HCV (nucleotide sequence as shown in SEQ ID NO: 38);

[0094] Control group 1 test solution 1-8: containing a specific second primer for HSV-1 (the nucleotide sequence is shown in SEQ ID NO: 39);

[0095] Control group 1 test solution 1-9: containing a second primer specific for HIV (nucleotide sequence as shown in SEQ ID NO: 40);

[0096] Control group 1 detection solution 1-10: contains a specific second primer for EV71 (the nucleotide sequence is shown in SEQ ID NO: 41).

[0097] Control group 2 test solution: It is the same as the experimental group test solution 1.

[0098] (1.2.3) Prepare test solution 2:

[0099] Experimental group detection solution 2-1: contains a specific first primer for VC; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 42), with a FAM fluorescent reporter group labeled at the 5' end and a DABCYL fluorescent quencher group labeled at the 3' end;

[0100] Experimental group detection solution 2-2: contains a specific first primer for Sal. Spp.; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 43), with ATTO fluorescent reporter group labeled at the 5' end and BHQ2 fluorescent quencher group labeled at the 3' end;

[0101] Experimental group test solution 2-3: contains a specific first primer for TB; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 44), with a HEX fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0102] Experimental group detection solution 2-4: contains a specific first primer for SH; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 45), with a ROX fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0103] Experimental group detection solution 2-5: contains a specific first primer for IAV; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 46), with a CY5 fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0104] Experimental group test solution 2-6: contains a specific first primer for HBV; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 47), with a TET fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0105] Experimental group detection solution 2-7: contains a specific first primer for HCV; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 48), with a CY5.5 fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0106] Experimental group detection solution 2-8: contains a specific first primer for HSV-1; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 49), with a Cy3 fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0107] Experimental group test solution 2-9: contains a specific first primer for HIV; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 50), with a Quasar705 fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end;

[0108] Experimental group detection solution 2-10: contains a specific first primer for EV71; and a specific target detection probe (nucleotide sequence as shown in SEQ ID NO: 51), with a Dylight755 fluorescent reporter group labeled at the 5' end and a BHQ2 fluorescent quencher group labeled at the 3' end.

[0109] Control group 1 test solution 2-1 to control group 1 test solution 2-10: they are the same as the experimental group test solution 2-1 to the experimental group test solution 2-10, respectively.

[0110] Control group 2 detection solution 2: contains specific first primers for VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 (the nucleotide sequences are shown in SEQ ID NOs: 12 to 21, respectively); and specific target detection probes (the nucleotide sequences are shown in SEQ ID NOs: 42 to 51, respectively).

[0111] (1.3) Extracting RNA from the sample to be tested:

[0112] Experimental group: Take 400μl RNA sample, add 100μl nucleic acid extract of the experimental group, mix and extract, the specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution (25mM HEPES, 200mM NaCl, 1.0% SDS, 5mM EDTA) to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by the experimental group extraction was obtained.

[0113] Control group 1: Take 400μl of RNA sample in 10 sample processing tubes, add nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-10 of control group 1 to each sample processing tube, mix well and extract respectively. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. Obtain the RNA of the sample to be tested extracted from control group 1 (each sample processing tube corresponds to one target RNA).

[0114] Control group 2: Take 400μl of RNA sample, add 100μl of nucleic acid extract of control group 2, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by extraction of control group 2 was obtained.

[0115] (1.4) The first stage amplification reaction:

[0116] Experimental group: Add 400 μl of experimental group detection solution 1 to the sample RNA extracted from the experimental group, mix well and react at 42°C for 10 minutes. Then add 250 μl of enzyme solution to the mixed solution, mix well and react at 42°C for 10 minutes to obtain the first stage amplification product of the experimental group.

[0117] Control group 1: Add 40 μl of control group 1 detection solution 1-1 to control group 1 detection solution 1-10 to each sample RNA to be tested in control group 1, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to each control group 1 mixed solution, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 1.

[0118] Control group 2: Add 40 μl of control group 2 detection solution 1 to the sample RNA extracted from control group 2, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to the mixture, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 2.

[0119] (1.5) Second stage amplification reaction:

[0120] Experimental group: The first-stage amplification product of the experimental group was packaged at 65 μl / reaction (i.e., the first-stage amplification product of the experimental group was packaged into 10 reaction units, and each reaction unit contained about 65 μl of the first-stage amplification product), and 35 μl of the experimental group detection solution 2-1 to the experimental group detection solution 2-10 was added to the 10 reaction units respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0121] Control group 1: 35 μl of control group 1 detection solution 2 (control group 1 detection solution 2-1 to control group 1 detection solution 2-10) were added to each first-stage amplification product of control group 1, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0122] Control group 2: 35 μl of control group 2 detection solution 2 was added to the first-stage amplification product of control group 2, followed by reaction at 42° C. for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0123] Figure 3 and Figure 4 The real-time fluorescence detection results of two repeated experiments of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 in the control group 1 and the experimental group are shown respectively (since none of the above 10 targets were detected in the control group 2, the real-time fluorescence detection results of the control group 2 are not shown). The amplification curves 1-10 in the figure represent VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 respectively. Figure 3 The results showed that the method used in control group 1 was able to detect all 10 target RNAs in the mixed test sample, indicating that each target detection system used had RNA detection capabilities; Figure 4 The results show that under the condition that the RNA template concentration of the sample to be tested is the same, the experimental group can also detect all 10 target RNAs in the mixed sample to be tested by the method of the present invention, and the amplification efficiency is basically the same as that of the control group 1. The difference between the control group 2 and the experimental group is that the detection solution 2 containing specific first primers for 10 target RNAs and specific target detection probes is directly added to the first-stage amplification product obtained in the second-stage amplification reaction. It may be due to the mutual interference between the primer pairs for different target RNAs that no target RNA is detected in the control group 2 (the statistical results of the amplification curve dt values ​​of the experimental group, the control group 1, and the control group 2 are shown in Table 2 below). The above results show that the method used in the control group 2 may have a strong inhibition on each target detection system when there are multiple pairs of primers and multiple different target detection probes in the second stage amplification reaction, resulting in a significant reduction in detection sensitivity, and one or more targets in the test sample RNA cannot be detected. The experimental group adopts the method of packaging the first stage amplification product before the second stage amplification reaction, and then adding an independent detection liquid 2 for each target RNA. It can be applied to detect all targets in the multi-target mixed test sample RNA, and the method has high sensitivity and detection range. At the same time, the experimental method used in the present invention only needs to perform one nucleic acid extraction and one first stage amplification reaction, and then the first stage amplification product is packaged (the number of packages is determined according to the number of target RNA species detected, and at least one reaction unit is packaged for each target RNA) and then the second stage amplification reaction and detection are performed, so that the detection of multiple target RNAs in the multi-target mixed test sample can be completed, which greatly improves the detection efficiency.

[0124] Table 2: Statistical results of dt values ​​of amplification curves of experimental group, control group 1 and control group 2

[0125]

[0126]

[0127] Example 2: Detection of a sample containing multiple target RNAs

[0128] In this embodiment, the sample RNA containing target RNA of VC, Sal.Spp., TB, SH, IAV, HBV, and HCV is detected, and the specific steps are as follows:

[0129] (2.1) Preparation of RNA samples to be tested:

[0130] Preparation of RNA samples: In this example, in vitro transcribed mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, and HCV (nucleotide sequences are shown in SEQ ID NOs: 2 to 8, respectively) were mixed as RNA samples to be tested. The RNA samples to be tested were diluted so that the concentration of each target RNA in the RNA samples to be tested was 5 copies / μl, and used as RNA samples for the following experimental groups, control groups 1, and control group 2.

[0131] (2.2) Preparation of experimental reagents:

[0132] (2.2.1) Preparation of nucleic acid extraction solution:

[0133] The nucleic acid extract of the experimental group contains specific first primers for VC, Sal.Spp., TB, SH, IAV, HBV, and HCV (the nucleotide sequences are shown in SEQ ID NOs: 12 to 18, respectively), and poly T-modified magnetic beads (solid support) of specific capture probes for each target (the nucleotide sequences of the specific capture probes for the above target RNAs are shown in SEQ ID NOs: 22 to 28, respectively).

[0134] Control group 1 nucleic acid extract-1 to control group 1 nucleic acid extract-7: they are the same as control group 1 nucleic acid extract-1 to control group 1 nucleic acid extract-7 prepared in Example 1 (1.2.1), respectively.

[0135] Nucleic acid extract of control group 2: It is the same as the nucleic acid extract of the experimental group.

[0136] (2.2.2) Preparation of test solution 1:

[0137] Experimental group detection solution 1: contains specific second primers for VC, Sal.Spp., TB, SH, IAV, HBV, and HCV (the nucleotide sequences are shown in SEQ ID NOs: 32 to 38, respectively).

[0138] Control group 1 detection solution 1-1 to control group 1 detection solution 1-7: they are respectively the same as control group 1 detection solution 1-1 to control group 1 detection solution 1-7 prepared in Example 1 (1.2.2).

[0139] Control group 2 test solution: It is the same as the experimental group test solution 1.

[0140] (2.2.3) Preparation of test solution 2:

[0141] Experimental group detection liquid 2-1 to experimental group detection liquid 2-7: they are respectively the same as the experimental group detection liquid 2-1 to experimental group detection liquid 2-7 prepared in Example 1 (1.2.3).

[0142] Control group 1 test fluid 2-1 to control group 1 test fluid 2-7: they are the same as the experimental group test fluid 2-1 to the experimental group test fluid 2-7, respectively.

[0143] Control group 2 detection solution 2: contains specific first primers for VC, Sal.Spp., TB, SH, IAV, HBV, and HCV (the nucleotide sequences are shown in SEQ ID NOs: 12 to 18, respectively); and specific target detection probes (the nucleotide sequences are shown in SEQ ID NOs: 42 to 48, respectively).

[0144] (2.3) Extracting RNA from the sample to be tested:

[0145] Experimental group: Take 400μl RNA sample, add 100μl nucleic acid extract of the experimental group, mix and extract, the specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by the experimental group extraction was obtained.

[0146] Control group 1: Take 400 μl of RNA sample in 7 sample processing tubes, add nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-7 of control group 1 to each sample processing tube, mix well and extract respectively. The specific extraction steps are as follows: heat at 60℃ for 10min; stand at room temperature for 10min; magnetize on the magnetic rack for 5min, discard the supernatant; add 1ml washing solution to resuspend; magnetize on the magnetic rack for 5min, discard the supernatant; add 1ml washing solution to resuspend; magnetize on the magnetic rack for 5min, discard the supernatant. Obtain the RNA of the sample to be tested extracted from control group 1 (each sample processing tube corresponds to one target RNA).

[0147] Control group 2: Take 400μl of RNA sample, add 100μl of nucleic acid extract of control group 2, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by extraction of control group 2 was obtained.

[0148] (2.4) The first stage amplification reaction:

[0149] Experimental group: Add 400 μl of experimental group detection solution 1 to the sample RNA extracted from the experimental group, mix well and react at 42°C for 10 minutes. Then add 250 μl of enzyme solution to the mixed solution, mix well and react at 42°C for 10 minutes to obtain the first stage amplification product of the experimental group.

[0150] Control group 1: Add 40 μl of control group 1 detection solution 1-1 to control group 1 detection solution 1-7 to each sample RNA to be tested in control group 1, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to each control group 1 mixed solution, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 1.

[0151] Control group 2: Add 40 μl of control group 2 detection solution 1 to the sample RNA extracted from control group 2, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to the mixture, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 2.

[0152] (2.5) Second stage amplification reaction:

[0153] Experimental group: The first-stage amplification product of the experimental group was packaged at 65 μl / reaction (i.e., the first-stage amplification product of the experimental group was packaged into 10 reaction units, and each reaction unit contained about 65 μl of the first-stage amplification product), and 35 μl of experimental group detection solution 2-1 to experimental group detection solution 2-7 was added to 7 of the 10 reaction units respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0154] Control group 1: 35 μl of control group 1 detection solution 2 (control group 1 detection solution 2-1 to control group 1 detection solution 2-7) were added to each first-stage amplification product of control group 1, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0155] Control group 2: 35 μl of control group 2 detection solution 2 was added to the first-stage amplification product of control group 2, followed by reaction at 42° C. for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0156] Figure 5-Figure 7 The real-time fluorescence detection results of two repeated experiments on VC, Sal.Spp., TB, SH, IAV, HBV, and HCV in the experimental group, control group 1, and control group 2 are shown respectively. Amplification curves 1-7 in the figure represent VC, Sal.Spp., TB, SH, IAV, HBV, and HCV respectively. Figure 6 The results showed that the method used in control group 1 was able to detect all seven target RNAs in the mixed test sample, indicating that each target detection system used had RNA detection capabilities; Figure 5 and Figure 7 The results showed that under the condition that the RNA template concentration of the sample to be tested was the same, the experimental group was also able to detect all 7 target RNAs in the mixed sample to be tested using the method of the present invention, and the amplification efficiency was basically consistent with that of the control group 1 (the statistical results of the amplification curve dt values ​​of the experimental group, the control group 1, and the control group 2 are shown in Table 3 below). The difference between the control group 2 and the experimental group was that in the second-stage amplification reaction, a detection solution 2 containing specific first primers and specific target detection probes for the 7 target RNAs was directly added to the first-stage amplification product obtained therefrom, and the detection solution 2 could only detect VC, but could not detect Sal.Spp., TB, SH, IAV, HBV, and HCV. The above results show that the method used in the control group 2 may have a strong inhibition on each target detection system when there are multiple pairs of primers and multiple different target detection probes in the second stage amplification reaction, resulting in a significant reduction in detection sensitivity, and one or more targets in the test sample RNA cannot be detected. The experimental group adopts the method of packaging the first stage amplification product before the second stage amplification reaction, and then adding an independent detection liquid 2 for each target RNA. It can be applied to detect all targets in the multi-target mixed test sample RNA, and the method has high sensitivity and detection range. At the same time, the experimental method used in the present invention only needs to perform one nucleic acid extraction and one first stage amplification reaction, and then the first stage amplification product is packaged (the number of packages is determined according to the number of target RNA species detected, and at least one reaction unit is packaged for each target RNA) and then the second stage amplification reaction and detection are performed, so that the detection of multiple target RNAs in the multi-target mixed test sample can be completed, which greatly improves the detection efficiency.

[0157] Table 3: Statistical results of dt values ​​of amplification curves of experimental group, control group 1 and control group 2

[0158] Detection object Experimental Group Control group 1 Control group 2 VC 14.4 14.9 21.1 Sal.Spp. 12.7 13.0 — TB 15.5 14.5 — SH 15.5 15.5 — IAV 13.4 13.4 — HBV 16.7 16.8 — HCV 16.4 16.7 —

[0159] Example 3: Detection of a sample containing multiple target RNAs

[0160] In this embodiment, the sample to be tested containing the target RNA of VC, Sal.Spp., TB, SH, and IAV is detected, and the specific steps are as follows:

[0161] (3.1) Preparation of RNA samples to be tested:

[0162] Preparation of RNA samples: In this example, in vitro transcribed mRNAs of VC, Sal.Spp., TB, SH, and IAV (nucleotide sequences are shown in SEQ ID NOs: 2 to 6, respectively) were mixed as RNA samples to be tested. The RNA samples to be tested were diluted so that the concentration of each target RNA in the RNA samples to be tested was 5 copies / μl, and used as RNA samples for the following experimental groups, control groups 1, and control groups 2.

[0163] (3.2) Preparation of experimental reagents:

[0164] (3.2.1) Preparation of nucleic acid extraction solution:

[0165] The nucleic acid extract of the experimental group contains specific first primers for VC, Sal.Spp., TB, SH, and IAV (the nucleotide sequences are shown in SEQ ID NOs: 12 to 16, respectively), and poly T-modified magnetic beads (solid support) of specific capture probes for each target (the nucleotide sequences of the specific capture probes for the above target RNAs are shown in SEQ ID NOs: 22 to 26, respectively).

[0166] Nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-5 of control group 1: they are respectively the same as nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-5 of control group 1 prepared in Example 1 (1.2.1).

[0167] Nucleic acid extract of control group 2: It is the same as the nucleic acid extract of the experimental group.

[0168] (3.2.2) Preparation of test solution 1:

[0169] The test solution 1 of the experimental group contained specific second primers for VC, Sal.Spp., TB, SH and IAV (the nucleotide sequences were shown in SEQ ID NOs: 32 to 36, respectively).

[0170] Control group 1 detection solution 1-1 to control group 1 detection solution 1-5: they are respectively the same as control group 1 detection solution 1-1 to control group 1 detection solution 1-5 prepared in Example 1 (1.2.2).

[0171] Control group 2 test solution: It is the same as the experimental group test solution 1.

[0172] (3.2.3) Preparation of test solution 2:

[0173] Experimental group detection liquid 2-1 to experimental group detection liquid 2-5: they are respectively the same as the experimental group detection liquid 2-1 to experimental group detection liquid 2-5 prepared in Example 1 (1.2.3).

[0174] Control group 1 test fluid 2-1 to control group 1 test fluid 2-5: they are the same as the experimental group test fluid 2-1 to the experimental group test fluid 2-5, respectively.

[0175] Control group 2 detection solution 2: contains specific first primers for VC, Sal.Spp., TB, SH, and IAV (the nucleotide sequences are shown in SEQ ID NOs: 12 to 16, respectively); and specific target detection probes (the nucleotide sequences are shown in SEQ ID NOs: 42 to 46, respectively).

[0176] (3.3) Extracting RNA from the sample to be tested:

[0177] Experimental group: Take 400μl RNA sample, add 100μl nucleic acid extract of the experimental group, mix and extract, the specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by the experimental group extraction was obtained.

[0178] Control group 1: Take 400 μl of RNA sample in 5 sample processing tubes, add nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-5 of control group 1 to each sample processing tube, mix well and extract respectively. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. Obtain the RNA of the sample to be tested extracted from control group 1 (each sample processing tube corresponds to one target RNA).

[0179] Control group 2: Take 400μl of RNA sample, add 100μl of nucleic acid extract of control group 2, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by extraction of control group 2 was obtained.

[0180] (3.4) The first stage amplification reaction:

[0181] Experimental group: Add 400 μl of experimental group detection solution 1 to the sample RNA extracted from the experimental group, mix well and react at 42°C for 10 minutes. Then add 250 μl of enzyme solution to the mixed solution, mix well and react at 42°C for 10 minutes to obtain the first stage amplification product of the experimental group.

[0182] Control group 1: Add 40 μl of control group 1 detection solution 1-1 to control group 1 detection solution 1-5 to each test sample RNA of control group 1, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to each control group 1 mixed solution, mix well and react at 42°C for 5 minutes to obtain each first-stage amplification product of control group 1.

[0183] Control group 2: Add 40 μl of control group 2 detection solution 1 to the sample RNA extracted from control group 2, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to the mixture, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 2.

[0184] (3.5) Second stage amplification reaction:

[0185] Experimental group: The first-stage amplification product of the experimental group was packaged at 65 μl / reaction (i.e., the first-stage amplification product of the experimental group was packaged into 10 reaction units, and each reaction unit contained about 65 μl of the first-stage amplification product), and 35 μl of experimental group detection solution 2-1 to experimental group detection solution 2-5 were added to 5 of the 10 reaction units respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0186] Control group 1: 35 μl of control group 1 detection solution 2 (control group 1 detection solution 2-1 to control group 1 detection solution 2-5) were added to each first-stage amplification product of control group 1, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0187] Control group 2: 35 μl of control group 2 detection solution 2 was added to the first-stage amplification product of control group 2, followed by reaction at 42° C. for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0188] Figure 8-Figure 10 The real-time fluorescence detection results of two repeated experiments on VC, Sal.Spp., TB, SH, and IAV in the experimental group, control group 1, and control group 2 are shown respectively. Amplification curves 1-5 in the figure represent VC, Sal.Spp., TB, SH, and IAV respectively. Fig. 9The results showed that the method used in control group 1 was able to detect all five target RNAs in the mixed test sample, indicating that each target detection system used had good RNA detection capabilities; Figure 8 and Fig.10 The results showed that under the condition that the RNA template concentration of the sample to be tested was the same, the experimental group was also able to detect all five target RNAs in the mixed sample to be tested using the method of the present invention, and the amplification efficiency was basically consistent with that of the control group 1 (the statistical results of the amplification curve dt values ​​of the experimental group, control group 1, and control group 2 are shown in Table 4 below). The difference between the control group 2 and the experimental group was that in the second-stage amplification reaction, a detection solution 2 containing specific first primers for the five target RNAs and specific target detection probes was directly added to the first-stage amplification product obtained therefrom, and the detection solution 2 could only detect VC, but could not detect Sal.Spp., TB, SH, and IAV. The above results show that the method used in the control group 2 may have a strong inhibition on each target detection system when there are multiple pairs of primers and multiple different target detection probes in the second stage amplification reaction, resulting in a significant reduction in detection sensitivity, and one or more targets in the test sample RNA cannot be detected. The experimental group adopts the method of packaging the first stage amplification product before the second stage amplification reaction, and then adding an independent detection liquid 2 for each target RNA. It can be applied to detect all targets in the multi-target mixed test sample RNA, and the method has high sensitivity and detection range. At the same time, the experimental method used in the present invention only needs to perform one nucleic acid extraction and one first stage amplification reaction, and then the first stage amplification product is packaged (the number of packages is determined according to the number of target RNA species detected, and at least one reaction unit is packaged for each target RNA) and then the second stage amplification reaction and detection are performed, so that the detection of multiple target RNAs in the multi-target mixed test sample can be completed, which greatly improves the detection efficiency.

[0189] Table 4: Statistical results of dt values ​​of amplification curves of experimental group, control group 1 and control group 2

[0190] Detection object Experimental Group Control group 1 Control group 2 VC 14.6 14.5 20.1 Sal.Spp. 13.1 13.1 — TB 15.0 15.3 — SH 15.1 15.3 — IVA 13.6 13.2 —

[0191] Example 4: Detection of a sample containing multiple target RNAs

[0192] In this embodiment, the sample to be tested containing the target RNA of VC, Sal.Spp., and TB is detected, and the specific steps are as follows:

[0193] (4.1) Preparation of RNA samples to be tested:

[0194] Preparation of RNA samples: In this example, in vitro transcribed mRNAs of VC, Sal.Spp., and TB (nucleotide sequences are shown in SEQ ID NOs: 2 to 4, respectively) were mixed as RNA samples to be tested. The RNA samples to be tested were diluted so that the concentration of each target RNA in the RNA samples to be tested was 5 copies / μl, and used as RNA samples for the following experimental group, control group 1, and control group 2.

[0195] (4.2) Preparation of experimental reagents:

[0196] (4.2.1) Preparation of nucleic acid extraction solution:

[0197] The nucleic acid extract of the experimental group contains specific first primers for VC, Sal.Spp., and TB (the nucleotide sequences are shown in SEQ ID NOs: 12 to 14, respectively), and poly T-modified magnetic beads (solid support) for specific capture probes for each target (the nucleotide sequences of the specific capture probes for the above target RNAs are shown in SEQ ID NOs: 22 to 24, respectively).

[0198] Control group 1 nucleic acid extract-1 to control group 1 nucleic acid extract-3: they are the same as control group 1 nucleic acid extract-1 to control group 1 nucleic acid extract-3 prepared in Example 1 (1.2.1), respectively.

[0199] Nucleic acid extract of control group 2: It is the same as the nucleic acid extract of the experimental group.

[0200] (4.2.2) Preparation of test solution 1:

[0201] The test solution 1 of the experimental group contained specific second primers for VC, Sal. Spp., and TB (the nucleotide sequences were shown in SEQ ID NOs: 32 to 34, respectively).

[0202] Control group 1 detection solution 1-1 to control group 1 detection solution 1-3: they are respectively the same as control group 1 detection solution 1-1 to control group 1 detection solution 1-3 prepared in Example 1 (1.2.2).

[0203] Control group 2 test solution 1: It is the same as the test solution 1 of the experimental group.

[0204] (4.2.3) Prepare test solution 2:

[0205] Experimental group detection liquid 2-1 to experimental group detection liquid 2-3: they are respectively the same as the experimental group detection liquid 2-1 to experimental group detection liquid 2-3 prepared in Example 1 (1.2.3).

[0206] Control group 1 test fluid 2-1 to control group 1 test fluid 2-3: they are the same as the experimental group test fluid 2-1 to the experimental group test fluid 2-3, respectively.

[0207] Control group 2 detection solution 2: contains specific first primers for VC, Sal.Spp., and TB (the nucleotide sequences are shown in SEQ ID NOs: 12 to 14, respectively); and specific target detection probes (the nucleotide sequences are shown in SEQ ID NOs: 42 to 44, respectively).

[0208] (4.3) Extracting RNA from the sample to be tested:

[0209] Experimental group: Take 400μl RNA sample, add 100μl nucleic acid extract of the experimental group, mix and extract, the specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by the experimental group extraction was obtained.

[0210] Control group 1: Take 400 μl of RNA sample in 3 sample processing tubes, add nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-3 of control group 1 to each sample processing tube, mix well and extract respectively. The specific extraction steps are as follows: heat at 60℃ for 10min; stand at room temperature for 10min; magnetize on the magnetic rack for 5min, discard the supernatant; add 1ml washing solution to resuspend; magnetize on the magnetic rack for 5min, discard the supernatant; add 1ml washing solution to resuspend; magnetize on the magnetic rack for 5min, discard the supernatant. Obtain the RNA of the sample to be tested extracted from control group 1 (each sample processing tube corresponds to one target RNA).

[0211] Control group 2: Take 400μl of RNA sample, add 100μl of nucleic acid extract of control group 2, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml of washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of the sample to be tested obtained by extraction of control group 2 was obtained.

[0212] (4.4) The first stage amplification reaction:

[0213] Experimental group: Add 400 μl of experimental group detection solution 1 to the sample RNA extracted from the experimental group, mix well and react at 42°C for 10 minutes. Then add 250 μl of enzyme solution to the mixed solution, mix well and react at 42°C for 10 minutes to obtain the first stage amplification product of the experimental group.

[0214] Control group 1: Add 40 μl of control group 1 detection solution 1-1 to control group 1 detection solution 1-3 to each sample RNA to be tested in control group 1, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to each control group 1 mixed solution, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 1.

[0215] Control group 2: Add 40 μl of control group 2 detection solution 1 to the sample RNA extracted from control group 2, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to the mixture, mix well and react at 42°C for 5 minutes to obtain the first stage amplification product of control group 2.

[0216] (4.5) Second stage amplification reaction:

[0217] Experimental group: The first-stage amplification product of the experimental group was packaged at 65 μl / reaction (i.e., the first-stage amplification product of the experimental group was packaged into 10 reaction units, and each reaction unit contained about 65 μl of the first-stage amplification product), and 35 μl of experimental group detection solution 2-1 to experimental group detection solution 2-3 were added to 3 of the 10 reaction units respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0218] Control group 1: 35 μl of control group 1 detection solution 2 (control group 1 detection solution 2-1 to control group 1 detection solution 2-3) were added to each first-stage amplification product of control group 1, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0219] Control group 2: 35 μl of control group 2 detection solution 2 was added to the first-stage amplification product of control group 2, followed by reaction at 42° C. for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0220] Figure 11-13 The real-time fluorescence detection results of two repeated experiments on VC, Sal.Spp., and TB in the experimental group, control group 1, and control group 2 are shown respectively. Amplification curves 1-3 in the figure represent VC, Sal.Spp., and TB respectively. Fig.12 The results showed that the method used in control group 1 was able to detect all three target RNAs in the mixed test sample, indicating that each target detection system used had good RNA detection capabilities; Fig.11 and Fig.13The results show that under the condition of the same RNA template concentration of the sample to be tested, the experimental group can also detect all three target RNAs in the mixed sample to be tested by the method of the present invention, and the amplification efficiency is basically the same as that of the control group 1 (the statistical results of the amplification curve dt values ​​of the experimental group, the control group 1, and the control group 2 are shown in Table 5 below), and the difference between the control group 2 and the experimental group is that in the second stage amplification reaction, the detection solution 2 containing the specific first primer and the specific target detection probe for the three target RNAs is directly added to the first stage amplification product obtained therefrom, and it can only detect VC, but cannot detect Sal.Spp., TB. The above results show that when the method used by the control group 2 has multiple pairs of primers and multiple different target detection probes in the second stage amplification reaction, it may have a strong inhibition on each target detection system, resulting in a significant reduction in the detection sensitivity, and it is impossible to detect one or more targets in the sample RNA to be tested, while the experimental group adopts the method of packaging the first stage amplification product before the second stage amplification reaction, and then adding an independent detection solution 2 for each target RNA. It can be applied to the detection of all targets in the multi-target mixed sample RNA to be tested, and this method has a high sensitivity and detection range. At the same time, the experimental method adopted in the present invention only requires one nucleic acid extraction and one first-stage amplification reaction, and then the first-stage amplification product is packaged (the number of packages is determined according to the number of target RNA types to be detected, and at least one reaction unit is packaged for each target RNA) and then the second-stage amplification reaction and detection are carried out, so as to complete the detection of multiple target RNAs in a multi-target mixed test sample, thereby greatly improving the detection efficiency.

[0221] Table 5: Statistical results of dt values ​​of amplification curves of experimental group, control group 1 and control group 2

[0222]

[0223]

[0224] The results of the above examples 1-4 show that the method and system used in the present invention can detect multiple target RNAs in a multi-target mixed test sample with high efficiency and high sensitivity. It only requires one nucleic acid extraction and one first-stage amplification reaction, and then the first-stage amplification product is packaged (the number of packages is determined according to the number of target RNA species detected, and at least one reaction unit is packaged for each target RNA) and then the second-stage amplification reaction and detection are performed to complete. However, the method and system of the present invention (for example, a system for a multi-target mixed test sample) can also be applied to the detection of a test sample containing a single target RNA, as described in the following examples 5 and 6.

[0225] Example 5: Detection of a sample containing a single target RNA by a detection system for multiple target RNAs

[0226] In this embodiment, a detection system for multiple target RNAs is used to detect a sample containing a single target RNA (VC, Sal.Spp., TB, SH or IAV), and the specific steps are as follows:

[0227] (5.1) Preparation of RNA samples to be tested:

[0228] Preparation of RNA samples: In this example, in vitro transcribed mRNAs of VC, Sal.Spp., TB, SH, and IAV (nucleotide sequences are shown in SEQ ID NOs: 2 to 6, respectively) were used as RNA samples to be tested. The concentration of each RNA sample to be tested was diluted to 5 copies / μl and used as RNA samples of the experimental group, control group 1, and control group 2.

[0229] (5.2) Preparation of experimental reagents:

[0230] (5.2.1) Preparation of nucleic acid extraction solution:

[0231] Experimental group nucleic acid extract: It is the same as the experimental group nucleic acid extract prepared in Example 3 (3.2.1).

[0232] Nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-5 of control group 1: they are the same as nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-5 of control group 1 prepared in Example 3 (3.2.1).

[0233] Nucleic acid extract of control group 2: It is the same as the nucleic acid extract of the experimental group.

[0234] (5.2.2) Preparation of test solution 1:

[0235] Experimental group test solution 1: It is the same as the experimental group test solution 1 prepared in Example 3 (3.2.2).

[0236] Control group 1 detection solution 1-1 to control group 1 detection solution 1-5: they are respectively the same as control group 1 detection solution 1-1 to control group 1 detection solution 1-5 prepared in Example 3 (3.2.2).

[0237] Control group 2 test solution 1: It is the same as the test solution 1 of the experimental group.

[0238] (5.2.3) Prepare test solution 2:

[0239] Experimental group detection liquid 2-1 to experimental group detection liquid 2-5: they are respectively the same as the experimental group detection liquid 2-1 to experimental group detection liquid 2-5 prepared in Example 3 (3.2.3).

[0240] Control group 1 test fluid 2-1 to control group 1 test fluid 2-5: they are the same as the experimental group test fluid 2-1 to the experimental group test fluid 2-5, respectively.

[0241] Control group 2 test solution 2: It is the same as the control group 2 test solution 2 prepared in Example 3 (3.2.3).

[0242] (5.3) Extracting RNA from the sample to be tested:

[0243] Experimental group: Take 400μl of each RNA sample in 5 sample processing tubes, add 100μl of nucleic acid extraction solution of the experimental group respectively, mix well and extract, the specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of each sample to be tested obtained by the experimental group extraction was obtained.

[0244] Control group 1: Take 400 μl of each RNA sample in 5 sample processing tubes, add control group 1 nucleic acid extract solution-1 to control group 1 nucleic acid extract solution-5 to each sample processing tube, mix well and extract respectively. The specific extraction steps are: heating at 60℃ for 10min; standing at room temperature for 10min; magnetizing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; magnetizing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; magnetizing on the magnetic rack for 5min, discarding the supernatant. Obtain the RNA of the sample to be tested extracted from control group 1 (each sample processing tube corresponds to one target RNA).

[0245] Control group 2: Take 400μl of each RNA sample in 5 sample processing tubes, add 100μl of nucleic acid extraction solution of control group 2 respectively, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. Obtain the RNA of each sample to be tested extracted by control group 2.

[0246] (5.4) The first stage amplification reaction:

[0247] Experimental group: Add 400 μl of experimental group detection solution 1 to each sample RNA extracted from the experimental group, mix well and react at 42°C for 10 minutes. Then add 250 μl of enzyme solution to each mixed solution, mix well and react at 42°C for 10 minutes to obtain the first-stage amplification products of each experimental group.

[0248] Control group 1: Add 40 μl of control group 1 detection solution 1-1 to control group 1 detection solution 1-5 to each sample RNA obtained in control group 1, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to each control group 1 mixed solution, mix well and react at 42°C for 5 minutes to obtain each first-stage amplification product of control group 1.

[0249] Control group 2: Add 40 μl of control group 2 detection solution 1 to each sample RNA extracted from control group 2, mix well and react at 42°C for 5 min. Then add 25 μl of enzyme solution to each mixed solution, mix well and react at 42°C for 5 min to obtain the first stage amplification product of control group 2.

[0250] (5.5) Second stage amplification reaction:

[0251] Experimental group: 65 μl / reaction of each first-stage amplification product of the experimental group was taken out and dispensed into new reaction units, and 35 μl of experimental group detection solution 2-1 to experimental group detection solution 2-5 were added thereto respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0252] Control group 1: 35 μl of control group 1 detection solution 2 (control group 1 detection solution 2-1 to control group 1 detection solution 2-5) were added to each first-stage amplification product of control group 1, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0253] Control group 2: 35 μl of control group 2 detection solution 2 was added to each first-stage amplification product of control group 2, followed by reaction at 42° C. for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0254] Figure 14-16 The real-time fluorescence detection results of two repeated experiments on VC, Sal.Spp., TB, SH, and IAV in the experimental group, control group 1, and control group 2 are shown respectively. Amplification curves 1-5 in the figure represent VC, Sal.Spp., TB, SH, and IAV respectively. Fig.15 The results showed that the method used in control group 1 was able to detect all five target RNAs, indicating that each target detection system used had good RNA detection capabilities; Fig.14 and Fig.16The results showed that under the condition that the RNA template concentration of the sample to be tested was the same, even if the experimental group used the nucleic acid extract and detection solution 1 containing all 5 target RNAs, the target RNA in each RNA sample could be detected and the amplification efficiency was basically the same as that of the control group 1 (the statistical results of the amplification curve dt values ​​of the experimental group, control group 1, and control group 2 are shown in Table 6 below). The difference between the control group 2 and the experimental group was that in the second-stage amplification reaction, the detection solution 2 containing the specific first primer and the specific target detection probe for all 5 target RNAs was directly added to each first-stage amplification product obtained therefrom. Due to the presence of multiple pairs of primers and multiple target detection probes in the second-stage amplification reaction, the detection system of each target RNA was strongly inhibited, resulting in a significant reduction in the detection sensitivity, and only VC could be detected, but Sal.Spp., TB, SH, and IAV could not be detected. The above results show that the method adopted by the control group 2 may have a strong inhibition on each target detection system when there are multiple pairs of primers and multiple target detection probes in the second-stage amplification reaction, resulting in a significant reduction in detection sensitivity, and failure to detect one or more target RNAs in the test samples containing a single target. The method adopted by the experimental group of adding an independent detection solution 2 for each target RNA in the second-stage amplification reaction can detect the target in the test sample containing any single target RNA, and this method has a high sensitivity and detection range.

[0255] Table 6: Statistical results of dt values ​​of amplification curves of experimental group, control group 1 and control group 2

[0256] Detection object Experimental Group Control group 1 Control group 2 VC 14.8 14.3 21.3 Sal.Spp. 12.6 12.8 — TB 15.3 15.4 — SH 15.4 15.6 — IAV 13.6 13.2 —

[0257] Example 6: Detection of a sample containing a single target RNA by a detection system for multiple target RNAs

[0258] In this embodiment, a detection system for multiple target RNAs is used to detect a sample containing a single target RNA (VC, Sal.Spp. or TB), and the specific steps are as follows:

[0259] (6.1) Preparation of RNA samples to be tested:

[0260] Preparation of RNA samples: In this example, in vitro transcribed mRNAs of VC, Sal.Spp., and TB (nucleotide sequences are shown in SEQ ID NOs: 2 to 4, respectively) were used as RNA samples to be tested. The concentration of each RNA sample to be tested was diluted to 5 copies / μl and used as RNA samples of the experimental group, control group 1, and control group 2.

[0261] (6.2) Preparation of experimental reagents:

[0262] (6.2.1) Preparation of nucleic acid extraction solution:

[0263] Experimental group nucleic acid extract: It is the same as the experimental group nucleic acid extract prepared in Example 4 (4.2.1).

[0264] Nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-3 of control group 1: they are the same as nucleic acid extract solution-1 of control group 1 to nucleic acid extract solution-3 of control group 1 prepared in Example 4 (4.2.1).

[0265] Nucleic acid extract of control group 2: It is the same as the nucleic acid extract of the experimental group.

[0266] (6.2.2) Preparation of test solution 1:

[0267] Experimental group test solution 1: It is the same as the experimental group test solution 1 prepared in Example 4 (4.2.2).

[0268] Control group 1 detection solution 1-1 to control group 1 detection solution 1-3: they are respectively the same as control group 1 detection solution 1-1 to control group 1 detection solution 1-3 prepared in Example 4 (4.2.2).

[0269] Control group 2 test solution 1: It is the same as the test solution 1 of the experimental group.

[0270] (6.2.3) Prepare test solution 2:

[0271] Experimental group detection liquid 2-1 to experimental group detection liquid 2-3: they are respectively the same as the experimental group detection liquid 2-1 to experimental group detection liquid 2-3 prepared in Example 4 (4.2.3).

[0272] Control group 1 test fluid 2-1 to control group 1 test fluid 2-3: they are the same as the experimental group test fluid 2-1 to the experimental group test fluid 2-3, respectively.

[0273] Control group 2 test solution 2: It is the same as the control group 2 test solution 2 prepared in Example 4 (4.2.3).

[0274] (6.3) Extracting RNA from the sample to be tested:

[0275] Experimental group: Take 400μl of each RNA sample in 3 sample processing tubes, add 100μl of nucleic acid extraction solution of the experimental group respectively, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. The RNA of each sample to be tested obtained by the experimental group extraction was obtained.

[0276] Control group 1: Take 400 μl of each RNA sample in 3 sample processing tubes, add control group 1 nucleic acid extract solution-1 to control group 1 nucleic acid extract solution-3 to each sample processing tube, mix well and extract respectively. The specific extraction steps are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. Obtain the RNA of the sample to be tested extracted from control group 1 (each sample processing tube corresponds to one target RNA).

[0277] Control group 2: Take 400μl of each RNA sample in 3 sample processing tubes, add 100μl of nucleic acid extraction solution of control group 2 respectively, mix well and extract. The specific steps of extraction are: heating at 60℃ for 10min; standing at room temperature for 10min; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant; adding 1ml washing solution to resuspend; adsorbing on the magnetic rack for 5min, discarding the supernatant. Obtain the RNA of each sample to be tested extracted by control group 2.

[0278] (6.4) The first stage amplification reaction:

[0279] Experimental group: Add 400 μl of experimental group detection solution 1 to each sample RNA extracted from the experimental group, mix well and react at 42°C for 10 minutes. Then add 250 μl of enzyme solution to each mixed solution, mix well and react at 42°C for 10 minutes to obtain the first-stage amplification products of each experimental group.

[0280] Control group 1: Add 40 μl of control group 1 detection solution 1-1 to control group 1 detection solution 1-3 to each sample RNA obtained in control group 1, mix well and react at 42°C for 5 minutes. Then add 25 μl of enzyme solution to each control group 1 mixed solution, mix well and react at 42°C for 5 minutes to obtain each first-stage amplification product of control group 1.

[0281] Control group 2: Add 40 μl of control group 2 detection solution 1 to each sample RNA extracted from control group 2, mix well and react at 42°C for 5 min. Then add 25 μl of enzyme solution to each mixed solution, mix well and react at 42°C for 5 min to obtain the first-stage amplification products of control group 2.

[0282] (5.5) Second stage amplification reaction:

[0283] Experimental group: 65 μl / reaction of each first-stage amplification product of the experimental group was taken out and dispensed into new reaction units, and 35 μl of experimental group detection solution 2-1 to experimental group detection solution 2-3 were added thereto respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0284] Control group 1: 35 μl of control group 1 detection solution 2 (control group 1 detection solution 2-1 to control group 1 detection solution 2-3) were added to each first-stage amplification product of control group 1, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0285] Control group 2: 65 μl / reaction of each first-stage amplification product of control group 2 was taken out and dispensed into new reaction units, and 35 μl of control group 2 detection solution 2 was added thereto respectively, followed by reaction at 42°C for 40 min, and real-time detection was performed using a real-time fluorescence quantitative PCR instrument.

[0286] Figure 17-Figure 19 The real-time fluorescence detection results of two repeated experiments on VC, Sal.Spp., and TB in the experimental group, control group 1, and control group 2 are shown respectively. Amplification curves 1-3 in the figure represent VC, Sal.Spp., and TB respectively. Fig.18 The results showed that the method used in control group 1 was able to detect all three target RNAs, indicating that each target detection system used had good RNA detection capabilities; Fig.17 and Fig.19The results showed that under the condition that the RNA template concentration of the sample to be tested was the same, even if the experimental group used the nucleic acid extract and detection solution 1 containing all three target RNAs, the target RNA in each RNA sample could be detected and the amplification efficiency was basically the same as that of the control group 1 (the statistical results of the amplification curve dt values ​​of the experimental group, control group 1, and control group 2 are shown in Table 7 below). The difference between the control group 2 and the experimental group was that in the second-stage amplification reaction, the detection solution 2 containing specific first primers and specific target detection probes for all three target RNAs was added to each first-stage amplification product obtained therefrom. Due to the presence of multiple pairs of primers and multiple target detection probes in its second-stage amplification reaction, the detection system of each target RNA was strongly inhibited, resulting in a significant reduction in the detection sensitivity, and only VC could be detected, but Sal.Spp. and TB could not be detected. The above results show that the method adopted by the control group 2 may have a strong inhibition on each target detection system when there are multiple pairs of primers and multiple target detection probes in the second-stage amplification reaction, resulting in a significant reduction in detection sensitivity, and failure to detect one or more target RNAs in the test samples containing a single target. The experimental group adopts the method of adding independent detection liquid 2 during the second-stage amplification, which can detect the target in the test sample containing any single target RNA, and this method has a higher sensitivity and detection range.

[0287] Table 7: Statistical results of dt values ​​of amplification curves of experimental group, control group 1 and control group 2

[0288] Detection object Experimental Group Control group 1 Control group 2 VC 14.5 14.7 19.8 Sal.Spp. 12.9 13.1 — TB 14.6 15.2 —

[0289] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A multi-target RNA amplification detection method for non-disease diagnosis purposes, comprising the following steps: 1) Extraction of multi-target RNA: Mixing a sample to be tested with a nucleic acid extract, extracting multi-target RNA in the sample to be tested, and obtaining an RNA sample; wherein the nucleic acid extract comprises a first primer and a capture probe specific to each target RNA in the multi-target RNA, the 3' end sequence of the first primer is a sequence that specifically binds to the corresponding target RNA, and the 5' end sequence is a promoter sequence, and the capture probe is used to capture the corresponding target RNA; 2) First stage amplification reaction: adding detection solution 1 and enzyme solution to the RNA sample obtained in step 1), mixing and reacting to obtain first stage amplification products; wherein the detection solution 1 contains a second primer specific to each target RNA in the multi-target RNA, the second primer is used to cooperate with the first primer to amplify the corresponding target RNA, and the enzyme solution contains reverse transcriptase and RNA polymerase; 3) Second-stage amplification reaction and fluorescence detection: The first-stage amplification product obtained in step 2) is packaged so that the number of reaction units after packaging is not less than the number of types of multi-target RNAs, and detection solutions 2 for different target RNAs are added to the packaged reaction units respectively, and after mixing, constant-temperature amplification reaction and fluorescence detection are performed to obtain qualitative determination results of each target RNA respectively; wherein the detection solution 2 for different target RNA contains a first primer and a target detection probe corresponding to the target RNA it targets.

2. The method according to claim 1, wherein in step 1), the promoter sequence is a T7 promoter sequence, the nucleotide sequence of which is shown in SEQ ID NO: 1; and / or The capture probe is connected to a solid support. Optionally, the content of the solid support in the nucleic acid extract is 50-500 mg / L; further optionally, the solid support is a magnetic particle; and / or The RNA is miRNA or non-miRNA, wherein the non-miRNA includes mRNA, rRNA, and tRNA.

3. The method according to claim 1 or 2, wherein the operation of step 1) comprises: 1-1) Mix the sample to be tested with the nucleic acid extract, incubate at 55-95°C for 10-15 minutes, let stand at room temperature until the mixture returns to room temperature, and magnetize on a magnetic stand for at least 5 minutes, and discard the supernatant; 1-2) adding washing solution to the product of step 1-1) to resuspend, adsorbing on a magnetic stand for 5 to 15 minutes, and discarding the supernatant; and 1-3) Repeat steps 1-2) to obtain RNA samples; Optionally, the washing solution in step 1-2) comprises: 5-50 mM HEPES, 50-500 mM NaCl, 0.5-1.5% SDS, and 1-10 mM EDTA.

4. The method according to any one of claims 1 to 3, wherein in step 1), the nucleic acid extract comprises: 250-800 mM HEPES, 4-10% LLS, 1-50 μM capture probe for each target, 50-500 mg / L solid support, and 0.01-2 μM first primer for each target.

5. The method according to any one of claims 1 to 4, wherein in step 2), The reaction conditions are: 37-45°C for 3-10 min; and / or The detection solution 1 comprises: 10-50 mM Tris, 20-90 mM KCl, 10-50 mM MgCl2, 0.1-10 mM NTPs, 0.1-10 mM dNTPs, 5-40% Glycerol, 0-25% DMSO, 0.01-2 μM second primer for each target; and / or The enzyme solution contains: 100-9000U reverse transcriptase, 100-5000U RNA polymerase, 20-100mM Tris, 0.1-1% TritonX-100, 30-300mM KCl, 0.01-0.5mM EDTA, 0.1-2mM DTT, and 20-50% Glycerol.

6. The method according to any one of claims 1 to 5, wherein in step 3), The detection solutions 2 for different target RNAs all contain: 10-50 mM Tris, 20-90 mM KCl, 10-50 mM MgCl2, 0.1-10 mM NTPs, 0.1-10 mM dNTPs, 5-40% Glycerol, 0-25% DMSO, 0.01-2 μM of a first primer corresponding to the target RNA, and 0.01-2 μM of a target detection probe corresponding to the target RNA; and / or The target detection probe is selected from any one of the following: molecular beacon, fluorescence resonance, scorpion probe, fluorescence amplification and molecular torch technology.

7. The method according to any one of claims 1 to 6, wherein in step 3), the reaction conditions for the isothermal amplification are: 37-45°C for 20-60 min.

8. The method according to any one of claims 1 to 7, wherein the multi-target RNA is selected from two or more mRNAs of the following: VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, EV71; wherein: The nucleotide sequences of the first primers for mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 12 to 21, respectively; The nucleotide sequences of the capture probes for mRNA of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 22 to 31, respectively; The nucleotide sequences of the second primers for mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 32 to 41, respectively; The nucleotide sequences of the target capture probes for mRNA of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 42 to 51, respectively.

9. A multi-target RNA amplification detection kit, comprising: Nucleic acid extract: it contains a first primer and a capture probe specific to each target RNA in multiple target RNAs, the 3' end sequence of the first primer is a sequence that specifically binds to the corresponding target RNA, and the 5' end sequence is a promoter sequence, and the capture probe is used to capture the corresponding target RNA; optionally, the nucleic acid extract contains: 250-800mM HEPES, 4-10% LLS, 1-50μΜ capture probe for each target, 50-500mg / L solid support, 0.01-2μΜ first primer for each target; Detection solution 1: comprising a second primer specific to each target RNA in the multi-target RNA, wherein the second primer is used to cooperate with the first primer to amplify the corresponding target RNA; optionally, the detection solution 1 comprises: 10-50 mM Tris, 20-90 mM KCl, 10-50 mM MgCl2, 0.1-10 mM NTPs, 0.1-10 mM dNTPs, 5-40% Glycerol, 0-25% DMSO, and 0.01-2 μΜ of the second primer for each target; Detection liquid 2: it includes a plurality of detection liquids 2 corresponding to each target RNA in the multiple target RNAs, and each detection liquid 2 contains a first primer and a target detection probe corresponding to its target RNA; optionally, each detection liquid 2 contains: 10-50mM Tris, 20-90mM KCl, 10-50mM MgCl2, 0.1-10mM NTPs, 0.1-10mM dNTPs, 5-40% Glycerol, 0-25% DMSO, 0.01-2μΜ of the first primer corresponding to the target RNA, 0.01-2μΜ of the target detection probe corresponding to the target RNA; and Enzyme solution: it contains reverse transcriptase and RNA polymerase; optionally, the enzyme solution contains: 100-9000U reverse transcriptase, 100-5000U RNA polymerase, 20-100mM Tris, 0.1-1% TritonX-100, 30-300mM KCl, 0.01-0.5mM EDTA, 0.1-2mM DTT, 20-50% Glycerol.

10. The kit according to claim 9, wherein the multi-target RNA is selected from two or more mRNAs of the following: VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, EV71; wherein: The nucleotide sequences of the first primers for mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 12 to 21, respectively; The nucleotide sequences of the capture probes for mRNA of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 22 to 31, respectively; The nucleotide sequences of the second primers for mRNAs of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 32 to 41, respectively; The nucleotide sequences of the target capture probes for mRNA of VC, Sal.Spp., TB, SH, IAV, HBV, HCV, HSV-1, HIV, and EV71 are shown in SEQ ID NOs: 42 to 51, respectively.